Editorial comment to “Impact of COVID-19 infection on the in-hospital outcome of patients hospitalized for heart failure with comorbid atrial fibrillation: Insight from National Inpatient Sample (NIS) database 2020”

IF 2.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Arrhythmia Pub Date : 2024-06-06 DOI:10.1002/joa3.13093
Yasushi Mukai MD, PhD
{"title":"Editorial comment to “Impact of COVID-19 infection on the in-hospital outcome of patients hospitalized for heart failure with comorbid atrial fibrillation: Insight from National Inpatient Sample (NIS) database 2020”","authors":"Yasushi Mukai MD, PhD","doi":"10.1002/joa3.13093","DOIUrl":null,"url":null,"abstract":"<p>Editorial comment to “Impact of COVID-19 infection on the in-hospital outcome of patients hospitalized for heart failure with comorbid atrial fibrillation: Insight from National Inpatient Sample (NIS) database 2020” by Wattanachayakul P, et al.<span><sup>1</sup></span></p><p>Numerous clinical studies have continuously reported the increased incidence and worse clinical outcomes of cardiovascular diseases associated with COVID-19. Relevant cardiovascular diseases include myocarditis, acute coronary syndrome, heart failure (HF), thromboembolisms, and arrhythmias.<span><sup>2</sup></span> It is also important to note that having COVID-19 results in more complicated clinical courses and higher mortalities in patients with preexisting cardiac conditions.<span><sup>3</sup></span> The present study by Wattanachayakul et al. utilized a big database of the US Healthcare systems and revealed a strong relation between COVID-19 infection and adverse outcomes in hospitalized HF patients with atrial fibrillation (AF).</p><p>A number of retrospective studies reported more severe conditions and a higher mortality among HF patients with COVID-19, and that HF was an independent risk factor for acute circulatory failure, renal failure, and multiorgan failure in patients with COVID-19.<span><sup>2</sup></span> It was also reported that COVID-19 infection is associated with an increasing incidence of atrial fibrillation.<span><sup>4</sup></span> A preexisting AF is associated with an increased mortality of over twofold in COVID-19 Patients.<span><sup>5</sup></span> From another aspect, the present study demonstrated that hospitalized HF patients with AF and COVID-19 had over threefold higher in-hospital mortality compared with those without COVID-19. More adverse outcomes such as prolonged length of stay or mechanical ventilation in the studied patients with COVID-19 were also striking. Whereas COVID-19 itself can elicit critical conditions, it is also conceivable that COVID-19 induces or even exacerbates HF and/or AF, which result in adverse clinical outcomes.</p><p>Cardiovascular involvement of COVID-19 can be largely explained by its inflammatory mechanisms called cytokine storm, myocardial damage, and relevant endothelial dysfunction.<span><sup>2</sup></span> Adverse effects of COVID-19 on cardiac function may also include an increased adrenergic drive because of fever and hypoxemia, which increases myocardial damage along with cardiomyocyte infection and cytokine storm. An increased inflammatory response is also related to the occurrence of AF.<span><sup>2, 4</sup></span> Indeed, atrial electrical instability and atrial tissue remodeling could be elicited in relation to various cytokine signaling. In addition to systemic inflammation, local mechanisms that contribute to atrial electrical instability associated with COVID-19 have been considered.<span><sup>4</sup></span> Angiotensin-converting enzyme-2 (ACE-2) has been identified as a functional receptor at cellular membrane for coronaviruses. ACE-2 is expressed in pneumocytes, macrophages, endothelial cells, pericytes, and cardiomyocytes and thus should be ubiquitously expressed in the atrial wall. In a normal condition, ACE-2 acts as a suppressor of angiotensin II (AngII)-induced cellular signaling. Ang II-induced signaling lead to myocyte hypertrophy, vasoconstriction, tissue fibrosis, and an increased oxidative stress, most of which is associated with AF occurrence and persistence. Binding of ACE-2 with SARS-CoV-2 results in a functional reduction of ACE-2 at the cellular membrane, which may augment Ang II-induced signaling. Such local mechanisms may be involved in the occurrence and exacerbation of AF and adverse clinical outcomes in patients with cardiovascular diseases and COVID-19.</p><p>Adverse effects of COVID-19 on the cardiovascular system exert a wide range of morbidity including AF and are associated with worse clinical outcomes. Future investigations are needed to further understand how to manage such clinically difficult conditions.</p><p>The authors declare no conflict of interests for this article.</p>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"40 4","pages":"903-904"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13093","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arrhythmia","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/joa3.13093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Editorial comment to “Impact of COVID-19 infection on the in-hospital outcome of patients hospitalized for heart failure with comorbid atrial fibrillation: Insight from National Inpatient Sample (NIS) database 2020” by Wattanachayakul P, et al.1

Numerous clinical studies have continuously reported the increased incidence and worse clinical outcomes of cardiovascular diseases associated with COVID-19. Relevant cardiovascular diseases include myocarditis, acute coronary syndrome, heart failure (HF), thromboembolisms, and arrhythmias.2 It is also important to note that having COVID-19 results in more complicated clinical courses and higher mortalities in patients with preexisting cardiac conditions.3 The present study by Wattanachayakul et al. utilized a big database of the US Healthcare systems and revealed a strong relation between COVID-19 infection and adverse outcomes in hospitalized HF patients with atrial fibrillation (AF).

A number of retrospective studies reported more severe conditions and a higher mortality among HF patients with COVID-19, and that HF was an independent risk factor for acute circulatory failure, renal failure, and multiorgan failure in patients with COVID-19.2 It was also reported that COVID-19 infection is associated with an increasing incidence of atrial fibrillation.4 A preexisting AF is associated with an increased mortality of over twofold in COVID-19 Patients.5 From another aspect, the present study demonstrated that hospitalized HF patients with AF and COVID-19 had over threefold higher in-hospital mortality compared with those without COVID-19. More adverse outcomes such as prolonged length of stay or mechanical ventilation in the studied patients with COVID-19 were also striking. Whereas COVID-19 itself can elicit critical conditions, it is also conceivable that COVID-19 induces or even exacerbates HF and/or AF, which result in adverse clinical outcomes.

Cardiovascular involvement of COVID-19 can be largely explained by its inflammatory mechanisms called cytokine storm, myocardial damage, and relevant endothelial dysfunction.2 Adverse effects of COVID-19 on cardiac function may also include an increased adrenergic drive because of fever and hypoxemia, which increases myocardial damage along with cardiomyocyte infection and cytokine storm. An increased inflammatory response is also related to the occurrence of AF.2, 4 Indeed, atrial electrical instability and atrial tissue remodeling could be elicited in relation to various cytokine signaling. In addition to systemic inflammation, local mechanisms that contribute to atrial electrical instability associated with COVID-19 have been considered.4 Angiotensin-converting enzyme-2 (ACE-2) has been identified as a functional receptor at cellular membrane for coronaviruses. ACE-2 is expressed in pneumocytes, macrophages, endothelial cells, pericytes, and cardiomyocytes and thus should be ubiquitously expressed in the atrial wall. In a normal condition, ACE-2 acts as a suppressor of angiotensin II (AngII)-induced cellular signaling. Ang II-induced signaling lead to myocyte hypertrophy, vasoconstriction, tissue fibrosis, and an increased oxidative stress, most of which is associated with AF occurrence and persistence. Binding of ACE-2 with SARS-CoV-2 results in a functional reduction of ACE-2 at the cellular membrane, which may augment Ang II-induced signaling. Such local mechanisms may be involved in the occurrence and exacerbation of AF and adverse clinical outcomes in patients with cardiovascular diseases and COVID-19.

Adverse effects of COVID-19 on the cardiovascular system exert a wide range of morbidity including AF and are associated with worse clinical outcomes. Future investigations are needed to further understand how to manage such clinically difficult conditions.

The authors declare no conflict of interests for this article.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19感染对合并心房颤动的心力衰竭住院患者院内预后的影响 "的社论:来自2020年全国住院病人样本(NIS)数据库的启示"
Wattanachayakul P 等人撰写的 "COVID-19 感染对合并心房颤动的心力衰竭住院患者院内预后的影响:Wattanachayakul P 等人撰写的 "COVID-19 感染对合并心房颤动的心力衰竭住院患者院内预后的影响:来自 2020 年全国住院患者抽样(NIS)数据库的启示 "1的编辑评论。相关的心血管疾病包括心肌炎、急性冠状动脉综合征、心力衰竭(HF)、血栓栓塞和心律失常。2 同样重要的是,患有 COVID-19 的患者的临床病程会更复杂,原有心脏病患者的死亡率会更高。Wattanachayakul 等人的这项研究利用了美国医疗保健系统的大型数据库,揭示了 COVID-19 感染与心房颤动(房颤)住院高频患者不良预后之间的密切关系。一些回顾性研究报告称,感染 COVID-19 的高频患者病情更严重,死亡率更高,而且高频是 COVID-19 患者发生急性循环衰竭、肾功能衰竭和多器官功能衰竭的独立危险因素。5 从另一个角度来看,本研究表明,与未感染 COVID-19 的患者相比,合并房颤和 COVID-19 的住院高血压患者的院内死亡率高出三倍多。研究中,COVID-19 患者的住院时间延长或机械通气等不良后果也很突出。COVID-19对心血管的影响在很大程度上可以用它的炎症机制--细胞因子风暴、心肌损伤和相关的内皮功能障碍--来解释。COVID-19 对心脏功能的不良影响还可能包括发热和低氧血症导致肾上腺素能驱动增加,从而加重心肌细胞感染和细胞因子风暴对心肌的损伤。2、4 事实上,心房电不稳定和心房组织重塑可能与各种细胞因子信号传导有关。4 血管紧张素转换酶-2(ACE-2)已被确认为冠状病毒细胞膜上的功能受体。ACE-2 在肺炎细胞、巨噬细胞、内皮细胞、周细胞和心肌细胞中均有表达,因此应在心房壁中普遍表达。在正常情况下,ACE-2 是血管紧张素 II(AngII)诱导的细胞信号传导的抑制因子。血管紧张素 II 诱导的信号传导导致心肌细胞肥大、血管收缩、组织纤维化和氧化应激增加,其中大部分与房颤的发生和持续有关。ACE-2 与 SARS-CoV-2 结合会导致细胞膜上的 ACE-2 功能降低,这可能会增强 Ang II 诱导的信号传导。COVID-19 对心血管系统的不良影响可导致包括房颤在内的多种疾病,并与更差的临床预后有关。未来的研究需要进一步了解如何处理这种临床难题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Arrhythmia
Journal of Arrhythmia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.90
自引率
10.00%
发文量
127
审稿时长
45 weeks
期刊最新文献
Issue Information Dementia risk reduction between DOACs and VKAs in AF: A systematic review and meta-analysis Electro-anatomically confirmed sites of origin of ventricular tachycardia and premature ventricular contractions and occurrence of R wave in lead aVR: A proof of concept study The Japanese Catheter Ablation Registry (J-AB): Annual report in 2022 Slow left atrial conduction velocity in the anterior wall calculated by electroanatomic mapping predicts atrial fibrillation recurrence after catheter ablation—Systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1